target upgrad unit state go sg websit
robust fy guidanc line
upsid tp
jnj result guidanc broadli line consensu
estim driven pharma upgrad forecast reflect
better-than-expect pharma show higher long-term margin
increas tp also benefit higher pharma sector
multipl despit volatil relat litig asbesto opioid
believ compani remain proxi healthcar industri
continu perform line sector last month
hold reiter tp increas vs
nc chang
compani better pharma sale grew line
sge consensu driven pharma sale medic devic
sale consum sale fell bit short
consensu expect immunolog one-third pharmaceut revenu
remicad sale declin less expect simponi stelara improv
line consensu expect howev sale recent launch tremfya
next gener psoriasi direct competitor novarti cosentyx
lilli taltz increas fell slightli short consensu cancer gener cut
velcad sale expect surpris regard rest
portfolio xarelto anticoagul partner bayer us sale slightli
better consensu adjust ep line consensu
guidanc line expect ye compani guid report
revenu broadli line consensu
adjust ep consensu alreadi high end guidanc rang
valuat share bounc back summer low rel
perform remain line pharma sector one year increas
estim reflect better-than-expect perform product
darzalex imbruvica oper profit leverag lt oper margin
dcf vs previous also roll forward sotp dcf model one
year pharma sector multipl expand compani trade line
pharma sector despit weaker earn growth outlook compound-annual-growth-rate vs
sector reflect benefit diversif med-tech visibl
stronger pharma longer durat asset lower volatil
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
main takeaway confer call
tremfya psoriasi direct competitor cosentyx novarti taltz eli lilli
grew yoy captur psoriasi market us compani
also anticip potenti approv psoriat arthriti indic us/eu
stelara immunolog psoriasi mainli grew yoy driven
crohn diseas indic improv yoy us market share
erleada prostat cancer manag grow us market share launch
progress countri compani hope gain approv metastat castrate-
sensit prostat cancer eu
xarelto cardio flat quarter volum growth off-set rebat due
increas size doughnut hole along higher utilis
darzalex blood cancer continu grow strongli yoy driven new
medic multipl myeloma transplant-inelig popul outsid us
driven increas penetr market share gain expect approv
subcutan formul patient relaps refractori multipl myeloma
us/eu
zytiga prostat cancer us revenu declin us due gener
competit partial off-set continu strong growth outsid us
remicad anti-tnf global revenu declin due increas discount
market share loss us biosimilar
medic devic saw acceler underli growth due
improv perform electrophysiolog double-digit growth consecut
year energi endocutt busi mid-single-digit growth contact lens
market growth orthopaed compani also focuss increas footprint
digital/robot surgeri busi addit acquir remain stake verb
surgic compani plan continu streamlin portfolio divestitur
acquisit partnership
consum segment grew underli rate littl global driven
dr ci labo acquisit well market share growth neutrogena aveeno
partial off-set roc divestitur
litig updat expect declin cash flow due payment relat
settlement opioid litig amount compani work
state attorney gener negoti committe finalis agreement principl
hope finalis agreement soon respect talc litig compani await
 remain activ front three segment expect remain
go forward complet acquisit along six licens agreement
compani expect continu tuck-in acquir new technolog howev
continu keep eye valu creation gener acquisit bear
mind actelion deal remain disappoint far
potenti us/eu approv
plan us/eu submiss
increas estim reflect better expect perform
product darzalex imbruvica oper profit leverag lt oper margin
dcf vs previous also roll forward sotp dcf
model one year moreov sinc last updat pharma sector multipl expand
valuat tp increas
averag pharma pharma vs previous
premium consum vs
target price compani trade slit premium vs pharma sector
reflect diversif med-tech visibl strong
multipl premium/discount
multipl premium/discount
multipl premium/discount
pharma sector
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jan cet
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
deriv target price sotp averag ev/ebita larg pharma multipl premium consum
med-tech pharma dcf lt growth lt ebita margin wacc
downsid risk slow portfolio rejuven like lead slowdown absenc acquisit patent expiri xarelto
neurosci product weigh growth
upsid risk cancer product darzalex imbruvica other stelara immune-inflamm help off-set gradual
eros tail product midterm
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
